Revolving Mibiton Fund invests in the Life Sciences infrastructure of

MI BITON I NVESTS I N NOVEL LI FE SCI ENCES I N FRASTRUCTU RE
C ontent
The Hague, 19 December 2014
Mibiton facility
SurgVision BV
>>
Revolving Mibiton Fund invests in the Life
Sciences infrastructure of SurgVision, Cristal
Therapeutics, Flowid and Genalice
Mibiton facility
Cristal Therapeutics BV
>>
Mibiton facility
Flowid BV
>>
Please find below an overview of our most recent investments, which fortify the
product-development infrastructure at four innovative Dutch Life Science companies.
In 2015, we will continue our 20-years revolving investment policy to strengthen the
Dutch Life Sciences community.
Mibiton facility
Genalice BV
>>
Mibiton Share, Solo
and Science funds
>>
Groningen investment
Multispectral Normalized Imaging System
enabling real time surgery guidance
SurgVision is a spin-off company of the Technical University of Munich and has
recently signed a clinical collaboration agreement with the University Medical Center
Groningen. The company develops innovative real-time imaging technology to assist
in the complete removal of cancerous tumour tissue during surgery. The SurgVision
Imaging Platform is a technology called ‘Multispectral Normalized Imaging’, which
combines hardware, intelligent software algorithms and fluorescently-labelled antibodies. Mibiton will finance three advanced instrumental clinical set-ups.
Ton van den Hoven: “SurgVision is pleased to have Mibiton’s support, which enables
the placement of three advanced clinical imaging platforms within well-renowned
institutions. This will help to meet the milestones in the process of taking this new
technology to the market. It will also enable SurgVision to direct its working capital
towards completing the clinical schedule.”
Contact information:
Surgvision B.V.
Dalhuysenstraat 37
8448 EW HEERENVEEN
+31(0)6 11 78 78 55
[email protected]
www.surgvision.com
<<
Maastricht investment
Laboratory Equipment for the novel Cristal
Therapeutics facility at the BioPartner Centre
Maastricht
Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicines based on its polymeric technology platform CriPec®. The application of
CriPec® results in better efficacy and improved tolerability of drugs by improved disposition in the body and controlled exposure to the sites of action. The first product
in development by Cristal Therapeutics is the CriPec® docetaxel for the treatment
of solid tumours. In addition to CriPec® docetaxel, the Cristal Therapeutics product
portfolio comprises various early-stage products in various therapeutic areas.
Cristianne Rijcken: “With the Mibiton investment, our laboratories can be equipped
to enable the pharmaceutical development of novel CriPec®-based products. More
specifically, the focus is on organic synthesis, formulation and stability studies and
corresponding analytical evaluations and product characterisation. The in-house
equipment is highly instrumental in the development of the first product CriPec®
docetaxel towards clinical evaluation and further expansions of the CriPec® platform
into other product opportunities, also for third parties.”
Contact information:
Cristal Therapeutics B.V.
Cristianne Rijcken
Oxfordlaan 55
6229 EV MAASTRICHT
+31 (0)43 388 5868
[email protected]
www.cristaltherapeutics.com
<<
Eindhoven investment
Spinning Disc Production - SpinPro
Flowid specializes in optimizing and developing production systems for the pharmaceutical and (bio)chemical industry. The Eindhoven University of Technology’s
spin-off has recently developed a pilot-size continuous plants platform ‘SpinPro’,
which can be used for the full-scale production of (bio)chemicals and pharmaceuticals. SpinPro is based on the so-called ‘spinning disc technology’. The system is
available as a reactor, particularly suited for multi-phase reactions, and as an extractor for the purification of medication, oils, natural ingredients and so much more.
The Mibiton investment will enable Flowid to manufacture a second generation of
SpinPro equipment.
Wouter Stam: “Mibiton helps us to expand our business with the funding of two
second generation SpinPro modular plants.”
Contact information:
Flowid B.V.
Postbus 513
Matrix MA 1.26-1.30
5600 MB EINDHOVEN
+31 (0)6 24 67 97 74
[email protected]
www.flowid.nl
<<
Gelderland investment
Accelerate configuration of GENALICE
VAULT servers to process Next Generation
Sequencing Data
GENALICE is a biomedical big data company with headquarters in Harderwijk,
Gelderland. The company designs and builds groundbreaking software solutions for
ultra-fast, highly accurate and cost-effective DNA data processing and analysis on
general-purpose hardware. The lead product, GENALICE MAP, designed to effectively process Next Generation Sequencing (NGS) data, is deployed on an all-inone appliance, the GENALICE VAULT. To tailor the NGS data procession solution to
specific needs, five configurations are available, enabling the storage and processing
of 500 (XS) to 10,000 (XL) full Human Genomes. Mibiton will finance the hardware
components of a number of GENALICE VAULT systems in order to accelerate market
acceptance.
Jos Lunenberg, Chief Business Officer, is very pleased with the loan agreement
provided by Mibiton, and commented as follows: “For a high potential company
like GENALICE, active in an extremely dynamic market, reducing the time to market
is essential. The support of Mibiton enables us to speed up our product delivery at
exactly the right moment. The acceptation process for this agreement was fast and
the funds were transferred to our bank account before the ink was dry.”
Contact information:
Genalice B.V.
Deventerweg 9d
3843 GA HARDERWIJK
+31 (0)88 122 1000
[email protected]
www.genalice.com
<<
Mibiton Share, Solo and Science funds
Are you as a Life Sciences SME planning to invest in facilities or equipment to start
or extend your business activities? Financial arrangements by the Mibiton Solo fund
will enable you to buy specialized or more general equipment to furnish your laboratory. With the Mibiton Share or Science funds, you can finance collaborations to
share the exploitation of high value Life Sciences facilities.
[email protected]
www.mibiton.nl
<<

Download Report